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Enumeration and molecular characterization of
circulating tumor cells isolated from peripheral blood
of patients with cancer can aid selection of targeted
therapy for patients, monitoring of response to
therapies and optimization of drug development,
while also providing valuable information about
intratumoral heterogeneity.solid tumors was recognized more than a century ago [8],Introduction
With the advent of therapies that target the specific
molecular aberrations driving a cancer, the traditional
concept of ‘one treatment fits all’ is evolving to ‘one
patient, one treatment’. Furthermore, as tumors adapt to
the selection pressures of serial targeted drugs through
the evolution of drug-resistant clones, their genomic
landscape changes over time, and hence treatments need
to be tailored accordingly [1]. Thus, treatment strategies
will almost invariably progress further to ‘one patient at
one moment in time, one treatment’.
The endeavor for precision medicine demands that
each patient be molecularly characterized and that robust
and validated ‘real-time’ assays are made in order to evalu-
ate tumor evolution. Although the study of tumor biopsies
or surgical specimens remains the ‘gold standard’ for
molecular characterization in clinical trials testing a bio-
marker [2,3], single-sample analyses fail to represent the
heterogeneous genomic evolution of tumors [4]. Consider-
ing the physical, logistical and ethical limitations of repeat-
ing multiple tumor biopsies in patients, biomarkers that
could be judged through minimally invasive procedures,
such as blood draws, constitute an opportunity for pro-
gression in precision medicine.* Correspondence: johann.de-bono@icr.ac.uk
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creativecommons.org/publicdomain/zero/1.0/)Circulating tumor cells (CTCs), which are shed into
the bloodstream from solid tumors, are relatively rare,
representing only one in more than a million blood cells
[5]. Patients with metastatic cancer are more likely to
have detectable CTCs in the bloodstream [6], but CTCs
also exist in patients with localized disease, even after
primary radical treatment, when their presence is inform-
ative of recurrence risk [7]. Although the presence of
cancer cells in the systemic circulation of patients with
it is only in the past two decades that the ability to isolate
CTCs has enabled their molecular characterization and
their use as prognostic and response biomarkers.
CTCs provide the opportunity to assess the biological
features of cancer repeatedly during the evolution of the
disease, enabling clinicians to react quickly to treat the
patient with the most suitable specific targeted therapy.
Here, we review the clinical studies to date on the use of
CTCs as biomarkers of cancer development and discuss
the promise of CTC analysis to guide clinical decision-
making and to aid targeted drug development.Identification of circulating tumor cells: technical
aspects
Methods to capture CTCs from blood rest on their dif-
ferential physical or immunologic characteristics. The
basis for affinity-binding systems used for CTC ‘enrich-
ment’ is the selection of cells expressing certain antigens,
such as epithelial cell-adhesion molecules (EpCAMs),
and the discard of those cells expressing antigens that
are known to be absent on epithelial cells but expressed
by other blood cells, such as leukocyte-expressed CD45.
Alternatively, CTCs can be isolated based on their dis-
tinct physical (size or deformability) or electromagnetic
properties [9-11]. The enriched CTC population is then
evaluated using an imaging system and, although count-
ing can be completely automated, this step usually re-
quires a certain degree of input from a human operator
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Figure 1 Visualization of circulating tumor cells (CTCs) after
isolation with the CellSearch semiautomated system
(Janssen Diagnostics). (a) Two CTCs from a blood sample from a
cancer patient. Both cells have an oval morphology and have a
diameter >4 μm. The nucleus is visible with DAPI (DAP) and they are
positively stained for epithelial markers (cytokeratins, CK) but not for
CD45 (a leukocyte marker). (b) Two ‘events’ identified as CTCs by the
automated system but that were discarded by the trained human
operator as each does not fulfill the characteristics of a CTC. APC,
allophycocyanin; PE, phycoerythrin.
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it is crucial to obtain analytical validation (assay sensitivity,
specificity and predictive value must be robust and con-
stant) and evidence of the clinical significance of any
results obtained. In 2011, the semi-automated CellSearch
system (Janssen Diagnostics) became the first US Food
and Drug Administration-cleared assay for quantitative
analysis of CTCs, based on its high reproducibility [5] and
the prognostic value demonstrated in prostate, breast and
colorectal cancer studies [12–14]. This platform selects
CTCs from blood samples according to size, presence
of a visible nucleus and markers of epithelial origin
(EpCAM, CD8, CD18 and CD19 positivity and absence of
CD45) [15].
There are several promising capture platforms in
development; a separate article in this special issue
comprehensively reviews the advances in isolation and
characterization of CTCs [16]. Potential advantages
offered by some of the methods in progress include: first,
a lack of a need for protein-based enrichment with the
Epic Sciences platform, which retains all nucleated cells
and permits their study with a high-definition scanner,
allowing for a more complex characterization of CTCsand direct observation of ‘clusters’ of cells [17]; second,
capturing higher amounts of CTCs with microfluidic
platforms (CTC-chips) [18,19]; and, third, the possibility
of continuous capturing of CTCs from blood by using
detectors inserted into the patient´s veins or apheresis-
based approaches with subsequent ex vivo CTC isolation
[20,21]. This last method enables the screening of CTCs
over larger volumes of blood, which could be relevant
for monitoring residual disease in early stages of cancer,
when low counts are expected.
Clinical utility of circulating tumor cell counts
Prognostic value
The number of CTCs present in the bloodstream of
patients with metastatic cancer is prognostic for overall
survival in several tumor types, with robust evidence
reported for prostate, breast and colorectal cancer [12-14].
In metastatic castration-resistant prostate cancer
(mCRPC), the prognostic value of baseline CTC counts
was first assessed in the IMMC38 trial, a study in-
cluding 164 patients about to start first-line chemother-
apy (81% received docetaxel, and the remainder received a
docetaxel-containing regimen). A high count of CTCs at
baseline (defined as ≥5 CTCs in 7.5 ml blood) was asso-
ciated with a significantly shorter survival compared with
having low counts at baseline (11.5 versus 21.7 months;
P < 0.0001). CTC counts were better indicators of survival
than levels of prostate-specific antigen (PSA) (Figure 2)
[13,22]. Further clinical trials in mCRPC have confirmed
these findings [23].
A study by Cristofanilli established the prognostic
value of CTC counts in advanced breast cancer. Patients
with metastatic breast cancer were tested for CTCs at
the time of starting a new line of treatment (either hor-
monal, chemotherapy or other treatments; 83 patients
were assessed before the first line of systemic treat-
ment, whereas 92 had received previous therapies).
Patients with ≥5 CTCs per 7.5 ml blood had the
worst progression-free survival (2.7 months versus
10 months; P < 0.001) and overall survival (10.1 months
versus >18 months; P < 0.001). In a multivariate analysis
including several molecular and clinical prognostic fac-
tors, CTC counts were a strong independent prognostic
factor [24].
In the setting of metastatic colorectal cancer, the prog-
nostic significance of CTCs was prospectively evaluated
in 430 patients before starting a new line of chemo-
therapy. Patients were stratified based on CTC levels of ≥3
versus <3 per 7.5 ml blood. Patients in the ‘unfavorable
prognosis’ group had shorter overall survival (9.4 months
versus 18.5 months; P < 0.001) and progression-free sur-
vival (4.5 months versus 7.9 months; P = 0.0002) [14].
Pilati and colleagues also concluded that CTCs were prog-
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Figure 2 Prognostic and predictive value of circulating tumor cell (CTC) counts in metastatic castration-resistant prostate cancer
(mCRPC). (a) Survival curves (Kaplan-Meier) of a group of 276 patients with mCRPC who were about to start a new line of chemotherapy,
showing how patients with <5 CTCs per 7.5 ml blood (‘favorable’ CTC count; green line) had a better prognosis than the group of patients with
higher counts (red line). (b) Differential survival curves representing outcomes for patients according to the change in their CTC counts after
receiving treatment, which show that patients with a conversion from an ‘unfavorable’ to a ‘favorable’ count during the response to treatment
(blue line) experience longer survival than those without a CTC drop (red and orange lines). The green line is the survival curves for those
patients who have low CTC counts at the beginning to that study and whose counts remained low throughout the study. OS, overall survival;
HR, Haza-ratio; CI, confidence interval. Reprinted from [13] de Bono JS et al. Clin Cancer Res 2008, 14:6302-6309. (Copyright by American Association for
Cancer Research).
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surgery, suggesting that CTCs might help to stratify
the management of this population [25].
Clinical validation of CTC counts as prognostic bio-
markers is being pursued in advanced stages of other
tumor types, with promising results reported in lung
[26,27], melanoma [28], head and neck [29] or pancreatic
cancer [30].
Moreover, CTCs have also been demonstrated to
inform prognosis in earlier stages of the disease. A large
study analyzed their presence in 735 patients with
colorectal cancer undergoing surgery with curative intent.
CTC enrichment selected cells expressing carcinoembryo-
nic antigen, cytokeratin 19, cytokeratin 20 and/or CD-133.
Time to relapse and overall survival was significantly
poorer for those patients with detectable CTCs [31].
In early stages of breast cancer, CTCs were detected in
21.5% of 2,026 patients after surgery and before the start
of adjuvant chemotherapy. The presence of CTCs in this
population was an independent prognostic factor for
disease-free and overall survival [32].
Overall, CTC enumeration is a strong prognostic tool
in patients with advanced cancer and can help in patient
stratification. In earlier stages of cancer, there is high
hope that CTC enumeration could monitor residual
disease after radical treatment, although the counts in
this population would be generally low, and the analysis
would require a platform with very high sensitivity.
Markers of response
Changes in CTC counts as a result of anticancer treat-
ment have also been shown to be a reliable marker of
response to treatment in different clinical settings. In
mCRPC, the predictive value of changes in CTC counts
and the correlation with survival have an enhanced rele-
vance owing to the challenge of evaluating the response
to treatment by standard radiological parameters as
most of the metastatic disease is confined to the bones
[33,34]. The IMMC38 study, mentioned above, was the
first to correlate changes in CTC counts with clinical
outcome in mCRPC: those patients with a baseline high
CTC count that converted to a low count after chemo-
therapy had significantly better outcomes than those
patients whose counts remained high despite the treatment(Figure 2) [13]. These findings were later validated in
the randomized phase III study that led to the approval
of the CYP-17 inhibitor abiraterone (Zytiga, Janssen
Biotech) [35].
Similarly, conversion from an unfavorable to favorable
CTC count after 4 weeks of treatment (using a threshold
of 5 CTC per 7.5 ml blood) is a predictive biomarker of
response to first-line therapy for metastatic breast cancer
(progression-free survival of 9.4 months compared with
4.9 months for patients with high CTC counts at base-
line that remained high on therapy). Moreover, drops in
CTC counts upon treatment correlated with improved
overall survival [12]. CTCs offer an early readout of
response to treatment (4 weeks) instead of having to
wait until the appearance of changes in radiological
biomarkers, which might happen later; a study in 138
women with metastatic breast cancer receiving different
treatments compared the performance of CTCs (after
4 weeks of treatment) and radiological assessments (after
10 weeks), concluding that CTCs were a more robust
marker of patient outcome, and with a lower rate of
inter-reader variability in interpretation of results (0.7%
versus 15%) [36].
The value of CTC counts on treatment as an inde-
pendent marker of response is also well established in
metastatic colorectal cancer [14]. The study from Cohen
and colleagues confirmed that patients with low CTC
counts upon therapy had extended progression-free and
overall survival, and this predictive value was maintained
when assessed at different time-points throughout the
therapy. The cut-off value in this case for the favorable
versus unfavorable prognosis groups was 3 CTCs per
7.5 ml blood.
Almost every study judging CTC counts as response
markers in different cancer types has simplified the enu-
meration to a dichotomist variable (high or low count)
by using particular thresholds in different tumor types
instead of considering CTC counts as a continuous
variable; a combined analysis of CTC counts from
111 patients with metastatic breast cancer and 185
with mCRPC who participated in the IMMC-01 and
IMMC-38 clinical trials [13,24] supports this strategy
[37]. A study in mCRPC patients suggested that a
relative decrease (30%) from baseline CTC counts
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tivariate analyses [38].
Molecular characterization of tumors from
circulating tumor cells
Molecular profiling of circulating tumor cells
CTCs represent a valuable resource for studying the
molecular underpinnings of cancer in individual patients.
CTC analysis can support the delivery of precision anti-
cancer treatments, as specific biomarkers of response to
targeted drugs can be appraised.
Genomic- and proteomic-based assays can be used to
analyze CTCs and detect the presence or absence of key
signaling oncogenic aberrations. For instance, cytogen-
etic studies based on fluorescence in situ hybridization
have been used to describe the variability between CTCs,
tumor metastasis and primary prostatic cancers in
copy-number aberrations for the androgen receptor
and presence of TMPRSS2-ERG fusions and loss of the
tumor suppressor gene PTEN (encoding phosphatase and
tensin homolog) [39].
An example of how transcriptome studies in CTC
analysis can be clinically applicable was the assessment,
by RNA in situ hybridization studies, of how relative
changes during treatment in the expression of epithelial
and mesenchymal markers in CTCs from 11 patients
with metastatic breast cancer correlated with response
and prognosis [40].
As a result of recent progress in next-generation
sequencing techniques, it is now also possible to perform
whole-genome and transcriptome amplification from
single cells, such as CTCs [41]. Lohr and colleagues were
able to isolate single CTCs expressing PSA (assessed by
low-coverage single-cell RNA sequencing) from patients
with metastatic prostate cancer and sequenced the whole-
exome [42] despite the limited input material that can be
obtained from single CTCs, which remains the main chal-
lenge for such studies [43]. In the field of transcriptome
assays, Ramsköld and collaborators developed a platform
for efficient and robust single-cell RNA sequencing. In a
cohort of samples from patients with advanced melanoma
(a tumor of non-epithelial origin and therefore in which
EpCAM-based cell selection is not useful), these investiga-
tors were able to analyze the transcriptome from single
CTCs expressing melanoma markers [44].
Treatment selection and monitoring of drug resistance
As cancer subclonal composition and driver mutation
landscapes can change through the outgrowth of drug-
resistant subclones after exposure to systemic therapy, it
might also be important to assess whether predictive
biomarkers are present at the specific time of starting a
new line of targeted treatment, contrary to testing biop-
sies taken at earlier stages of the natural history of thedisease; a study on 254 patients with breast cancer
was able to detect overexpression of human epidermal
growth factor receptor 2 (HER2) in CTCs in almost one-
third of patients who had no HER2 overexpression in
the primary tumor [45]. This finding has tremendous
clinical relevance as overexpression of HER2 is a clinic-
ally validated predictive biomarker of response to HER2-
targeting therapies in breast cancer [46,47].
A proof-of-principle study in lung cancer detected
activating mutations in the gene encoding the epidermal
growth factor receptor (EGFR) in CTCs from 11 out of
the 12 patients tested; these patients were receiving
EGFR-targeting tyrosine kinase inhibitors, and inte-
restingly some of these mutations in CTCs had emerged
de novo (that is, were not present in the matched
primary tumor), suggestive of temporal evolution and a
putative acquired mechanism of resistance to therapy
[48]. Analogous results in patients with metastatic mel-
anoma receiving serine/threonine-protein kinase B-Raf
(BRAF) inhibitors, colorectal cancers patients treated
with anti-EGFR antibodies and patients with gastroin-
testinal stromal tumors during tyrosine-protein kinase
Kit/alpha-type platelet-derived growth factor receptor
(KIT/PDGFR)-targeting treatment [49-52] support per-
forming real-time analysis of predictive biomarkers of
response in cancer medicine, and minimally invasive
CTC-based studies represent an advance compared with
tumor biopsy samples for repetitive, real-time analysis.
Ideally, patients would start a targeted treatment, and
molecular indicators of response or resistance would be
assessed in CTCs and/or other circulating biomarkers
repeatedly over the course of treatment, guiding clinicians
regarding when to stop or switch the anticancer treat-
ment. A recent and successful example of this strategy is a
study that serially characterized CTCs from 58 patients
with mCRPC while receiving either enzalutamide or abira-
terone to study mechanisms of resistance; quantitative
reverse-transcription polymerase chain reaction was uti-
lized to interrogate the presence of splice variants of the
androgen receptor genes in CTCs. Antonarakis and
colleagues demonstrated that the splice variant 7 of the
androgen receptor (AR-V7) is a predictive factor of enza-
lutamide or abiraterone failure and, more interestingly,
that the appearance of AR-V7 during the course of treat-
ment in patients with no AR-V7 expression at baseline
might be a mechanism of acquired resistance to these
drugs [53].
Circulating tumor cell analysis to understand
intratumor heterogeneity
Genetic intra-tumor heterogeneity (ITH) has been discov-
ered across a wide range of solid tumor types. For ex-
ample, exome sequencing of multiple tumor regions from
clear-cell kidney tumors, the commonest type of renal
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somatic mutations and DNA copy-number aberrations
detected were present in every region that was analyzed
from an individual tumor [54]. Mutations or hypermethy-
lation of the VHL gene and loss of heterozygosity of
chromosome 3p were the only aberrations detected in all
analyzed regions from each tumor, suggesting that these
were early founder aberrations, whereas other molecular
aberrations, including mutations in members of the phos-
phoinositide 3-kinase/mammalian target of rapamycin
(PI3K/mTOR) pathway (that is, mTOR, TSC2, PTEN and
PIK3CA) amenable to be targeted with specific drugs,
were heterogeneous within individual tumors. Genetic
ITH has also been identified across many other solid
tumor types such as primary breast, gastric, bladder, pros-
tate and pancreatic cancers, where various degrees of gen-
etic ITH, ranging from intermixed subclones to spatially
separated subclones, have been described [54-58].
Integrating ITH in individualized treatment selections
remains an unmet clinical need in cancer medicine. Se-
quencing studies on CTCs allow heterogeneous mutations
to be captured, enabling a more detailed picture of ITH
and subclonal evolution in a single patient with a minim-
ally invasive approach. It is envisioned that the ana-
lysis of subclonal heterogeneity could help clinicians
to understand why cancer patients might not respond
homogeneously in different metastases to treatment with
a targeted drug and might eventually guide treatment
selection.
Using CTCs for ITH studies facilitates the inference of
subclonal structures. Genomic-profiling studies of individ-
ual CTCs isolated from patients with metastatic colorectal
cancer using the CellSearch platform showed how the
presence of some genomic aberrations in CTCs was
indicative of their subclonal origin from specific areas of
the original tumor, through array-comparative genomic
hybridization and multiplexed targeted sequencing of 68
genes relevant to colorectal cancer [41]. CTCs also further
permit the study of gene-expression signatures, including
dynamic drug-induced changes [59]. The functional inter-
rogation of CTCs might provide crucial insights into the
phenotypes of heterogeneous tumor subclones.
Circulating tumor cell studies to guide drug
development
Pharmacodynamics (PD) studies are crucial in modern
drug development to provide evidence for proof-of-
mechanism in early-phase clinical trials and support ‘go/
no go’ decisions about further development of new com-
pounds. Minimally invasive access to CTCs from patients
offers a unique opportunity to monitor the PD effect of
drugs in phase I clinical trials [60].
Assessment of PD biomarkers in CTCs can be per-
formed repeatedly over the course of treatment, whichrepresents an advantage compared with the study of
tumor biopsies. To serve as an example, Wang and col-
leagues developed a quantitative assay to monitor changes
in nuclear levels of the DNA damage marker histone vari-
ant γH2AX in CTCs that they then tested in samples from
15 patients with different cancer types participating in
diverse phase I trials [61]. Among them, an increase in the
nuclear γH2AX of CTCs as a response to therapy was
observed in five patients receiving DNA-repair targeting
drugs (topotecan, cyclophosphamide and/or inhibitors
of the poly (ADP-ribose) polymerase PARP). Later, a
phase I study of the PARP inhibitor Niraparib (MK-4827;
Merck/Tesaro) implemented quantitative (changes in CTC
counts over the course of treatment) and qualitative assess-
ment of CTCs (nuclear γH2AX expression) as exploratory
endpoints to support preliminary signs of antitumor
activity [62]. In this study of Niraparib, 21 patients
with mCRPC were treated, with no radiological responses
observed; however, several patients had significant drops
in CTC counts, which were especially remarkable in
the three patients with a time-to-progression of over
6 months.
Variations in CTC counts after drug exposure can also
provide an easy and rapid readout of PD effects: the
phase I trials of ARQ197 (a selective inhibitor of the
hepatocyte growth factor receptor c-MET) in patients
with different tumor types and EZN4176 (a second-
generation antisense oligonucleotide to exon 4 of the
androgen receptor) in prostate cancer assessed the
changes in CTC counts in patients in parallel to the de-
termination of the optimal doses of the drugs [63,64]
(Figure 3). Precisely in the setting of phase I clinical
trials, where patients with advanced stages of different
tumor types and commonly a short survival expectancy
are exposed to novel therapies, baseline CTC enumer-
ation is of value as an independent prognostic factor and
improves the performance of prognostic indexes used in
clinical practice to select patients for these studies [65].
CTC analysis in early clinical trials can also be used to
assess putative predictive biomarkers of response to
novel targeted treatment and to provide proof-of-mechan-
ism of novel compounds and a definition of biologically
active doses. Hotspot mutations in PIK3CA were identi-
fied in CTCs from patients with either colorectal or breast
cancer in two different studies [66,67]. Moreover, Kallergi
and collaborators [68] were able to assess the activation of
the PI3K-AKT-mTOR pathway in two groups of patients
with early (n = 16) and metastatic (n = 16) breast cancer,
reporting high expression levels of phospho-PI3K and
phospho-AKT in CTCs from both populations. These
results open the door to implementing such assays for pa-
tient selection in trials testing drugs against this important
oncogenic signaling pathway, as has been done previously
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Figure 3 Integrating quantitative and qualitative studies on circulating tumor cells (CTC) in early clinical trials. (a) Schematic
representation of how studying CTCs at different time-points during the treatment can provide information on drug effects (PD studies), discover
mechanisms of resistance and also assess changes in CTC counts as predictive markers of responses. (b) Changes in CTC counts compared with
baseline enumeration in patients participating in the phase I trial of the c-MET inhibitor ARQ-197. PD, pharmacodynamics. (Reprinted with permission
from [63] Yap TA et al. J Clin Oncol 2011, 29:1271-1279. (Copyright by American Society of Clinical Oncology. All rights reserved).
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CTC analysis is a validated method to study tumor
characteristics and aid clinical decision-making. This
minimally invasive approach facilitates repetitive analysis
over time. Analysis can be purely quantitative, which has
been proven to deliver prognostic and predictive infor-
mation at different stages of cancer, or can involve the
assessment of molecular biomarkers in CTCs. It is cru-
cial that the novel isolation platforms currently in devel-
opment are analytically and clinically validated to ensure
biomarker integrity.
One caveat for CTC studies is whether the whole bur-
den of disease contributes equally to the CTC pool or
whether some subclones of the disease might be under-
represented or absent in CTCs. Additionally, it is also
important to remember that the CellSearch system and
other enrichment platforms based on epithelial markers
might fail to recognize cells shed from non-epithelial can-
cers such as melanomas or sarcomas, in which disease-
specific technologic approaches and composite selection
criteria might be needed [70], or cells that have lost
expression of epithelial markers owing to undergoing an
epithelial-mesenchymal transition, a central part of the
invasion-metastasis process [71,72].
Molecular characterization of CTCs to guide rational
treatment selection has direct applicability in clinical
practice; it can help to overcome the inability of single
biopsies to portray accurately the genomic landscapes of
cancers and the limitations of multi-metastasis biopsy
approaches. The possibility of regularly re-assessing evolv-
ing cancers is extremely useful for on-going treatment
stratification and understanding primary and secondary
drug-resistance.
Nevertheless, the exact role of CTC counts in routine
clinical practice remains yet to be defined. On the
one hand, the costs and complexity associated with theenrichment and enumeration process (including kits and
operator time) are still high. On the other, a first clinical
trial evaluating the benefit from an early switch on sys-
temic treatment guided by changes in CTC counts after
the first cycle of treatment in metastatic breast cancer
recently failed to demonstrate significant benefit for this
strategy compared with maintaining treatment until
progression based on traditional endpoints [73]. However,
the strong prognostic and predictive value demonstrated
for CTCs in different tumor types and stages of the dis-
ease warrants further evaluation as a surrogate marker of
survival endpoints in other clinical scenarios, which could
change not only clinical practice but also the way clinical
trials are designed. Thus, overall, quantitative and qua-
litative studies of CTCs represent a promising tool to
advance toward the delivery of precision medicine to
cancer patients.Abbreviations
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